stockrowACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
- Revenue
- +22.9%
- EPS
- −27.9%
- Free cash flow
- +141.2%
Quarter to September 2026, against a year earlier
Follow ACAD
Alert me
ACADIA Pharmaceuticals Inc. (ACAD) Free cash flow
ACADIA Pharmaceuticals Inc.'s free cash flow for fiscal 2025 was $105.1M, down 33.1% from $157.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $82.0M. Over the past ten years it has ranged from −$218.6M (fiscal 2017) to $157.2M (fiscal 2024); the current reading is higher than 91% of that period. ACADIA Pharmaceuticals Inc. ranks 32nd of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $105.1M | (33.11%) |
| FY2024 | $157.2M | — |
| FY2023 | −$23.3M | — |
| FY2022 | −$114.0M | — |
| FY2021 | −$126.8M | — |
| FY2020 | −$143.8M | — |
| FY2019 | −$152.3M | — |
| FY2018 | −$169.6M | — |
| FY2017 | −$218.6M | — |
| FY2016 | −$217.9M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $10.3M | (89.27%) |
| Jun 2026 | $95.7M | 232.62% |
| Mar 2026 | $28.8M | — |
| Dec 2025 | −$52.7M | — |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. | $82.0M |
| PBLS Parabilis Medicines, Inc. compare | −$119.1M |
| TNGX Tango Therapeutics, Inc. compare | −$144.2M |
| IRON Disc Medicine, Inc. compare | −$197.5M |
| RLAY Relay Therapeutics, Inc. compare | −$212.2M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$216.1M |
| XENE Xenon Pharmaceuticals Inc. compare | −$338.5M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
| DYN Dyne Therapeutics, Inc. compare | −$480.4M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on ACAD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement